Spero Therapeutics Inc expected to post a loss of 10 cents a share - Earnings Preview

Spero Therapeutics

11/03/2024 20:26

* Spero Therapeutics Inc  SPRO.OQ   SPRO.O  is expected
to show a
fall in quarterly revenue when it reports  results on March 13
for the period ending December 31 2023
    * The Cambridge Massachusetts-based  company is expected to
report
a 60.7% decrease in revenue to $18.633 million from $47.44
million a year ago, according to the mean estimate from 3
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Spero Therapeutics Inc
is for
a loss of 10 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Spero
Therapeutics Inc is $7.50​, above​ its last closing price
of $1.66. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.02       -0.03      0.04      Beat    233.3
 Jun. 30 2023  -0.33       -0.34      -0.23     Beat    33
 Mar. 31 2023  -0.33       -0.33      -0.25     Beat    25​
 Dec. 31 2022              0.04       0.55      Beat    1,169.
                                                        3
 ​​Sep.        -0.31       -0.30      -0.33     Missed  -8.8
 30 2022                                                
 Jun. 30 2022  -0.92       -0.93      -0.87     Beat    6.1​
 Mar. 31 2022  -0.86       -0.87      -1.01     Missed  -16.2
 Dec. 31 2021  -0.78       -0.75      -0.90     Missed  -20.4
 This summary was machine generated March 11 at 20:26 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)